How does biology affect local therapy decisions?
Breast cancer represents a biologically diverse set of diseases. Previous data suggest that the estrogen/progesterone receptor (ER/PR) status and HER2/neu status are important determinants of prognosis and response to various systemic treatments. Recent data also suggest that these receptors correlate with outcomes of local-regional therapies. Specifically, patients with ER-positive HER2/neu-negative disease have an excellent outcome with radiation treatments, either given as a component of breast-conservative therapy (BCT) or for those with more advanced disease, when given after mastectomy. For patients with triple-negative disease, data suggest that the proportional benefits offered from radiation in reducing local-regional recurrences may be less. This article will highlight some of these data and discuss strategies for new local-regional research avenues that are based on breast cancer biologic subtype.